News

SNSP113 Gives Antibiotics More Punch Against Bacteria Often Seen in Cystic Fibrosis, Study Find

Synspira’s SNSP113 gives antibiotics more punch against the Burkholderia cepacia infections that cystic fibrosis patients experience, a study reports. The research, published in PLoS One, was titled “Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.” Lung infections caused by Burkholderia cepacia are difficult to…

Cystic Fibrosis Foundation Opens Door to Anthera Speeding Up Trial of Digestive Disorder Therapy

Anthera Pharmaceuticals has received news that could help it accelerate patient enrollment in a Phase 3 clinical trial of Sollpura (liprotamase) as a treatment for a digestive disorder known as cystic fibrosis-triggered exocrine pancreatic insufficiency. The news is that a key Cystic Fibrosis Foundation committee approved the company’s trial design. The sign-off…